Zevra Corp (ZVRA) - מקדם חוב לטווח ארוך להון

Zevra Therapeutics (ZVRA) specializes in developing orphan drugs with strict temperature-controlled shipping requirements, which ensures high margins. This chart illustrates a market price of 0.00, highlighting the business's independence from GDP and macroeconomic trends. The successful launch of products in the US market and stable management, having completed asset integration, ensure the company's sustainable growth within the neurobiology segment.

Zevra Therapeutics (ZVRA) investments in AI platforms for molecular simulation require evaluation through current long-term debt-to-equity dynamics. The ratio of liabilities with a maturity of over one year to total equity determines the degree of financial dependence and bankruptcy risk; a decrease in this coefficient indicates a strengthening balance sheet, although an excessive avoidance of leverage may limit return on equity.